研究报告 Research Report 9 Feb 2026 香港医疗 Hong Kong Health Care 医药行业周报（2026.02.02-2026.02.06）：市场情绪回暖；看好基本面表现强劲的创新药产业链龙头 Healthcare Weekly (2026.02.02-2026.02.06): Market Sentiment Warms; Bullish on Leaders in Innovative Drug Chain with Strong Fundamentals [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 华润医药 | | Outperform | | 京东健康 | Outperform 国药控股 | | Neutral | | 药明生物 | Outperform 映恩生物 | | Outperform | | 信达生物 | Outperform 金斯瑞生物科 ...

Core Viewpoint - The Hang Seng Technology ETF (520570) has seen significant inflows and positive performance, indicating a recovery in the Hong Kong stock market, particularly in the technology sector, following recent corrections [1][2]. Group 1: Market Performance - As of February 9, 2026, the Hang Seng Technology ETF (520570) rose by 1.14% with a turnover of 2.76%, amounting to 75.36 million yuan [1]. - The Hang Seng Technology Index components, including Huahong Semiconductor, JD Health, and SMIC, experienced gains of 4.79%, 4.31%, and 3.48% respectively [1]. - Southbound funds have consistently flowed into the Hong Kong stock market, with net inflows recorded for seven consecutive trading days as of February 6, 2026 [1]. Group 2: Fund Inflows - Southbound funds achieved a net buying amount exceeding 56 billion yuan in the week from February 2 to 6, marking the highest weekly inflow since late September of the previous year [1]. - On February 6, the net buying amount reached a recent high of 22.206 billion yuan, with the last three trading days seeing net purchases exceeding 10 billion yuan each [1]. Group 3: Investment Outlook - China Galaxy Securities suggests that the valuation attractiveness of Hong Kong stocks has increased following recent corrections, with expectations of a rebound in the market around the Chinese New Year [2]. - The technology sector remains a key focus for medium to long-term investments, with reduced valuation pressure and potential for recovery [2]. - The Hang Seng Technology Index includes the top 30 Hong Kong-listed companies highly related to technology themes, representing major players in sectors such as internet, fintech, cloud computing, e-commerce, and digital business [2].

Group 1 - The Hong Kong stock market saw a collective rise in AI application stocks, with notable increases such as Zhiyun up over 11% and Reading Group up 8% [1] - Other companies like Pony.ai, Fubo Group, and Xindong Company also experienced gains exceeding 6%, while Kingsoft Cloud and Dreamland Technology rose over 5% [1] - The report from Kaiyuan Securities highlighted ByteDance's launch of the Seedance 2.0 video generation model on the Jiemeng platform, which has sparked widespread evaluation and discussion in the AI industry due to its impressive performance [1] Group 2 - Zhiyun's stock price increased by 11.91% to 227.40, with a total market value of 101.39 billion and a year-to-date increase of 95.70% [2] - Reading Group's stock rose by 8.08% to 37.20, with a market capitalization of 37.99 billion and a year-to-date increase of 12.80% [2] - Other notable stock performances include Pony.ai up 6.46%, Fubo Group up 6.57%, and Xindong Company up 6.25%, with respective market values of 47.86 billion, 11.54 billion, and 41.69 billion [2]

Core Viewpoint - The Hong Kong stock market saw a collective rise in AI application stocks, indicating strong investor interest and confidence in the sector [1]. Group 1: Stock Performance - Zhihui Technology (智谱) surged over 11% [1] - Yuewen Group (阅文集团) increased by 8% [1] - Xiaoma Zhixing (小马智行), Fubo Group (阜博集团), Xindong Company (心动公司), and WeRide (文远知行) all rose over 6% [1] - Kingsoft Cloud (金山云), Chuangmeng Tiandi (创梦天地), and Minglue Technology (明略科技) experienced gains of over 5% [1] - MINIMAX-WP saw an increase of over 4% [1] - JD Health (京东健康), Chuangxin Qizhi (创新奇智), and Fanshi Intelligent (范式智能) rose over 3% [1] - Ping An Good Doctor (平安好医生) and Zhongyou Game (中手游) increased by nearly 3% [1]

Group 1 - The Hong Kong stock market saw a collective rise in AI application stocks, with notable increases such as Zhiyu up over 11% and Reading Group up 8% [1] - Other companies like Xiaoma Zhixing, Fubo Group, Xindong Company, and Wenyuan Zhixing experienced gains exceeding 6% [1] - The report from Kaiyuan Securities highlighted ByteDance's launch of the Seedance 2.0 video generation model on the Jiemeng platform, which has garnered significant attention and discussion within the AI industry due to its impressive performance [1] Group 2 - Zhiyu's stock rose by 11.91%, reaching a latest price of 227.400 with a total market value of 101.385 billion, marking a year-to-date increase of 95.70% [2] - Reading Group's stock increased by 8.08%, with a latest price of 37.200 and a market value of 37.999 billion, reflecting a year-to-date rise of 12.80% [2] - Xiaoma Zhixing's stock rose by 6.46%, priced at 110.400 with a market value of 47.863 billion, although it has seen a year-to-date decline of 5.88% [2]

Core Insights - The medical large model sector is experiencing significant advancements, particularly with the recent launches from OpenAI, Anthropic, and Google, indicating a competitive landscape in healthcare AI [1][3][4] - Domestic companies in China, such as Baichuan Intelligence and Ant Group, are making substantial progress, showcasing their capabilities and innovations in the medical AI field [5][6][10] Group 1: OpenAI's Developments - OpenAI launched ChatGPT Health and OpenAI for Healthcare, which comply with HIPAA regulations and aim to enhance patient care services [2] - ChatGPT Health integrates a new module based on the latest GPT-5 model, allowing users to connect personal health data while ensuring data privacy [2] - OpenAI for Healthcare targets medical institutions, offering enterprise-level solutions for clinical environments, including automated documentation [2] Group 2: Competitors' Responses - Anthropic released Claude for Healthcare, directly competing with OpenAI's offerings, highlighting its commitment to the healthcare sector [3] - Google updated its open-source medical large model, MedGemma 1.5, improving its capabilities in text, medical records, and medical imaging [3] Group 3: Domestic Innovations - Baichuan Intelligence launched Baichuan-M3, surpassing GPT-5.2 in benchmark tests, with a hallucination rate of only 3.5%, which was later improved to 2.6% [4][5] - Ant Group's medical model has gained significant traction, achieving 30 million monthly active users and doubling daily inquiries within a month [5] - JD Health and other domestic firms are also releasing new models and solutions, contributing to a vibrant competitive landscape in China's medical AI sector [5][10] Group 4: Benchmarking and Performance - HealthBench and MedBench are the primary benchmarking systems for evaluating medical large models, assessing safety, clinical applicability, and professional reasoning [7][8] - The performance of medical large models is crucial, with ongoing iterations and resource investments being necessary for advancements [8] Group 5: Industry Trends and Future Outlook - The medical large model sector is expected to grow significantly, with various domestic models emerging as strong contenders in 2026 [6][10] - The integration of local clinical guidelines and data security measures positions domestic models as more suitable for the Chinese market [6] - The increasing support from the government and the focus on localized solutions are likely to enhance the competitiveness of domestic models [6]

Core Insights - The report emphasizes the potential of the AI industry and high-growth segments like gaming, suggesting that recent market corrections present better entry opportunities [10][13][17]. E-commerce Sector - The e-commerce sector remains constrained by market sentiment and macroeconomic weakness, with low growth and profit expectations for Q4 [10][13]. - Alibaba's Qianwen App launched a 3 billion yuan subsidy campaign, achieving over 10 million orders in 9 hours, indicating a competitive AI agent market [10][13]. - Meituan's acquisition of Dingdong Maicai for approximately 50 billion yuan reflects a strategic move to strengthen its position in instant retail [10][14]. Social Entertainment Media - Bilibili and Tencent show strong advertising momentum, with Tencent's gaming fundamentals improving, particularly with the anticipated success of "Delta Action" [10][13][15]. - Bilibili's self-developed game "Shining! Luming" is set to release new products gradually in 2026, enhancing its product pipeline [10][15]. Internet Healthcare - JD Health and Alibaba Health leverage their leading platform advantages to deepen collaborations with upstream pharmaceutical manufacturers, resulting in strong revenue and profit growth [10][15]. Short Video Sector - Kuaishou's main business remains stable, with its AI technology leading in commercialization, optimizing user engagement and conversion data [10][15]. Trendy Play + IP Sector - Pop Mart announced the establishment of its European headquarters in London, planning to open 27 new stores in Europe, which will create over 150 jobs [10][15]. Long Video Sector - Multiple platforms are releasing quality series, with a focus on investment opportunities in iQIYI and Mango Excellent Media, which are currently at low valuations [10][15]. Music Streaming - Tencent Music and NetEase Cloud Music reported stable performance, although concerns about competition have led to valuation adjustments [10][16]. Gaming Sector - The gaming sector is expected to maintain its performance driven by fundamentals, with continued recommendations for leading companies like Tencent and NetEase [10][17]. - New game reserves from companies like Perfect World and 37 Interactive Entertainment are anticipated to boost performance through product launches [10][17]. Advertising Sector - The adjustment of Shuhua will not affect the operational trends of Focus Media, with increased advertising investments expected from internet advertisers in 2026 [10][18]. AI Sector - AI is driving accelerated growth in overseas CSP cloud revenues and orders, with a new round of AI model and product iterations emerging [10][19]. - Recommendations include focusing on major cloud players like Google and Amazon, as well as domestic giants like Alibaba and Tencent [10][19].

开盘后直线跳水，一条直线直接打到-2.2%，随后触底反弹，截至收盘恒生指数下跌1.21%。互联网跌幅 居前，大消费、科技等紧随其后，恒生医疗逆势红盘。 恒生互联网大幅低开后冲高回落，盘中一度大跌2.17%，截至收盘下跌1.19%。阿里巴巴下跌2.88%美团 下跌2.56%，快手下跌2.4%，地平线机器人、网易、百度等股跌幅均在2%上方。 大消费低开高走但整体弱势，截至收盘下跌0.93%。名创优品下跌4.42%，京东健康、老铺黄金、百济 神州、康师傅控股等跌幅均在2%上方；零跑汽车逆势上涨5.84%，理想汽车、蒙牛乳业等股涨幅均在 3%上方。 恒生医疗低开高走，逆势收涨，截至收盘上涨0.45%。其中药明康德上涨1.68%，中国生物上涨0.78%， 药明生物上涨0.43%。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ ...

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

Investment Rating - The report indicates a positive outlook for the pharmaceutical industry, with a recommendation for investment based on favorable fundamentals [17]. Core Insights - The Hong Kong pharmaceutical sector outperformed the Hang Seng Index in January, with the Hang Seng Healthcare Index rising by 8.6%, exceeding the index by 1.7 percentage points. This was driven by several factors, including profit warnings from CXO sector companies, advancements in internet healthcare, and supportive policies from the National Healthcare Security Administration (NHSA) for high-quality surgical robots [1][7]. - The NHSA has issued guidelines to support the pricing of high-quality surgical robots, allowing for premium pricing based on their advanced capabilities and precision in complex surgeries [3][15]. - The State Drug Administration continues to back the development of high-quality innovative drugs, emphasizing clinical value and providing market exclusivity for certain medications, including those for rare diseases and pediatric use [2][14]. Summary by Sections Industry Performance - The pharmaceutical industry in Hong Kong showed strong performance in January, with significant contributions from the CXO sector and internet healthcare companies like JD Health and Ark Health, which reported positive earnings forecasts [1][7]. Policy Support - Recent revisions to the Drug Administration Law emphasize support for innovative drug development, including streamlined approval processes and enhanced regulatory oversight to ensure drug safety and quality [2][14]. - The NHSA's new pricing guidelines for surgical robots aim to incentivize the use of advanced medical technologies, potentially leading to increased revenue for companies involved in this sector [3][15]. Company Recommendations - China Biologic Products (1177 HK) is expected to see double-digit sales growth by 2025, bolstered by its acquisition of Haogiya Biotech, which specializes in small nucleic acid drugs [4][16]. - WuXi AppTec (2359 HK) and WuXi Biologics (2269 HK) have also shown promising earnings forecasts, indicating a recovery in demand within the CXO sector [4][16]. - The report highlights the potential of leading medical AI platform companies, such as Insilico Medicine (3696 HK), which has secured multiple overseas licensing deals, reflecting high industry recognition for its capabilities in enhancing pharmaceutical R&D efficiency [4][16].